Ameriprise Financial Inc I Mab Transaction History

Ameriprise Financial Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $161,251 - $603,472	-12,859 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $163,279 - $268,647	-3,606 Reduced 21.9%	12,859 $609,000
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $941,468 - $1.39 Million	16,465 New	16,465 $1.19 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.1M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.